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                           “In all chaos there is a cosmos, in all disorder a secret order” 
 
                        “In ogni caos c'è un cosmo, in ogni disordine un ordine segreto” 
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1. INTRODUCTION 
 
Lung cancer continues to be the most common cause of cancer-related mortality worldwide. Every 
year, 1,8 million people are diagnosed with lung cancer and 1,6 million die of the disease (Ferlay et 
al. 2015). Almost 50% of all cases occur in the developing countries (Parkin et al. 2002). In the 
European Union (EU), lung cancer is the fourth most commonly diagnosed cancer, affecting more 
than 312,000 people every year and the main cause of cancer deaths with 267,700 deaths recorded 
in 2012 and it accounts for approximately 20% of all cancer deaths (ERS). In the United States in 
2007, there were 203,536 people diagnosed with lung cancer and of this number, 158,683 people 
died from the disease (Ferlay et al. 2015).  
Lung cancer was the most common cancer type among men, with 1.2 million new cases (16.7%) 
and almost 1.1 million deaths (23.6%), whereas in women the incidence was lower, with 583 000 
new cases (8.7%) and 491 000 deaths (13.8%)(Ferlay et al. 2015). Notably, the incidence of lung 
cancer in women has increased 4-fold in the last 30 years (Thomas et al. 2005). Adenocarcinoma is 
the most common type of cancer among females and lifetime never-smokers. Worldwide incidence 
of adenocarcinoma has increased, replacing squamous cell carcinoma as the most common subtype 
(Nakamura and Saji 2013). 
Despite the improvements in treatments during the last few decades, the prognosis of lung cancer is 
still poor and the 5 year survival rate is 15% in the United States, 10% in Europe and 9% in 
developing countries (Parkin 2005).The survival of lung cancer is closely related to the stage at the 
time of diagnosis, ranging from 70% for limited, stage I disease, to less than 5% for stage IV 
disease (Mountain et al. 1997). 
The most common cause of lung cancer is long-term exposure to tobacco smoke, which causes 80 – 
90% of all incidences (Hecht 2002). Nearly 10-25% of lung cancers worldwide occur in never 
smokers and the incidence of this disease among non-smokers is increasing in many countries (ELF 
2016). Large-scale studies suggest that a combination of genetic factors, exposure to radon gas, 
asbestos fibres, and air pollution, including second-hand smoke (Thun et al. 2008) should be 
associated with an increases risk of lung cancer (Stieb et al. 2015; Burnett et al. 2014). 
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1.1. Types of lung cancer 
Lung cancers are classified according to the histological types and the classification has important 
implications for the treatment and prognosis of the disease. There are two main categories: small 
cell lung cancer (SCLC, 20%) and non-small cell lung cancers (NSCLC, 85%) 
NSCLC is subdivided into three major histological subtypes: adenocarcinoma (40%), squamous cell 
carcinoma (30%), and large cell carcinoma (15%) (Herbst et al. 2008). A number of less common 
subtypes exist such as adenosquamous carcinoma (<5% of all lung cancers), sarcomatid carcinoma 
(<2% of all lung cancers) as well as very rare subtypes such as squamous cell papilloma (<0.5% of 
all lung cancers). Each of these types can be further classified into more specific subtypes (Travis et 
al. 2011). 
 
 
Figure 1.1 Classification of lung cancer 
 
1.1.1 Adenocarcinoma 
Adenocarcinoma is a subtype of non-small cell lung cancer (NSCLC). It tends to develop in smaller 
airways, such as bronchioles, and it is usually located more along the outer edges of the lungs. It is a 
very heterogeneous tumour in the pathologic and molecular perspectives. 
Therefore, in 2011 the International Association for the Study of Lung Cancer (IASLC), American 
Thoracic Society (ATS) and European Respiratory Society (ERS) developed a new pathologic 
classification for adenocarcinoma according to the predominant growth pattern into lepidic, acinar, 
papillary, solid and micropapillary variants (Travis et al. 2011). 
The IASLC/ATS/ERS classification system is independently associated with overall survival (OS) 
and disease recurrence in adenocarcinomas (Hung et al. 2014). The characteristics of patterns can 
be summarized as follows. 
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• Lepidic pattern: neoplastic cells growing along pre-existing alveolar structures; common 
septal widening with sclerosis; absence of papillary or micropapillary patterns and intra-
alveolar tumour cells. Lepidic predominant invasive tumors have been correlated with 
favourable prognosis in patients with resected lung adenocarcinoma (Lee et al. 2009). 
 
• Acinar pattern: glands which are round to oval-shaped with a central luminal space 
surrounded by tumour cells Cribriform arrangement; cord-like arranged tumour cells with an 
acinar “polarity” should also be considered as acinar. termediate prognosis (Russell et 
al.  2011). 
 
• Papillary pattern: growth of columnar cells along central fibrovascular core; papillary 
structures filled with alveolar spaces, even a tumour has lepidic growth; width and length of 
the stromal core is very variable in lung cancer. Intermediate prognosis (Russell et al.  2011 
 
• Solid pattern: polygonal tumour cells forming sheets which lack other recognizable patterns 
of adenocarcinoma; cohesive cell agglomerates in a nest-like configuration without acinar 
polarity are the hallmark of the solid growth pattern. It is reported that solid pattern is a poor 
prognostic factor in lung adenocarcinoma (Hung et al. 2014; Russell et al. 2011). 
 
• Micropapillary pattern: tumour cells growing in micropapillary tufts which lack 
fibrovascular cores; detached and/or connected tumour cells to alveolar walls; floating ring-
like glandular structures within alveolar spaces. Micropapillary patterns have been 
associated with an aggressive clinical course compared with traditional papillary 
adenocarcinoma and bronchioloalveolar carcinoma - poor prognosis - (Amin et al. 2002; 
Motoi et al. 2008). 
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Figure 1.2 Driver mutation spectrum, according to the novel IASLC/ATS/ERS classification 
Note: *Indicates samples harboring the PIK3CA mutation without overlap with other driver mutations. 
Abbreviations: IASLC, International Association for the Study of Lung Cancer; ATS, American Thoracic Society; ERS, 
European Respiratory Society; AAH, atypical adenomatous hyperplasia; AIS, adenocarcinoma in situ; MIA, minimally 
invasive adenocarcinoma; LEP, lepidic predominant; ACN, acinar predominant; PAP, papillary predominant; MP, 
micropapillary predominant; SLD, solid predominant; IMA, invasive mucinous adenocarcinoma. 
 
In adenocarcinoma driver genetic alterations occur in multiple oncogenes including: K-
RAS(26,9%), EGFR(9,4%), ALK (4%), MET(4%), PIK3CA(2,6%), RET (1,9%), ROS1(1,7%), 
BRAF(1,6%), HER2(0,9%). KRAS mutations are generally considered mutually exclusive with 
other driver events including EGFR, HER2 or BRAF mutations and ALK rearrangements (Sequist 
et al. 2011), although this statement seems questionable in the light of some recent reports. Indeed, 
the coexistence of EGFR/ALK and KRAS/ALK mutations in lung adenocarcinoma has been 
described in a few of studies (Sahnane et al. 2016; Sasaki et al. 2011; Rossi et al. 2011; Baldi et al. 
2014). 
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1.1.2 Squamous cell carcinoma 
Squamous cell carcinoma is a common form of lung cancer, accounting for approximately one-third 
of all cases of bronchogenic carcinomas. Squamous cell lung tumors usually occur in the central 
part of the lung or in one of the main airway branches (left or right bronchus). 
The great majority of patients with SCC are current or former heavy smokers, furthermore, this 
carcinomas are most strongly associated with smoking in a dose-dependent manner (Molina et al. 
2008; Ettinger et al. 2013); in contrast with adenocarcinoma, where a growing proportion are never-
smokers or former light smokers (Khuder et al. 2001; Weiss et al. 2010). Its histogenesis may be 
related to chronic inflammation and injury of the bronchial epithelium, which leads to replacement 
of the normal ciliated columnar epithelium by a squamous epithelium (Boffetta. 2004; Brambilla et 
al., 2001). This transformation from a glandular epithelium to squamous epithelium is known as 
squamous metaplasia. Most squamous cell carcinomas arise centrally from either the main, lobar or 
segmental bronchi and ulcerate through the mucosa into the surrounding lung parenchyma. Their 
central location also tends to produces symptoms at an earlier stage than tumours located 
peripherally (Boffetta. 2004). 
Lung SCC is a heterogeneous group of diseases and can be subdivided into 4 either histological or 
molecular subtypes: classical, primitive, basal, and secretory (Wilkerson et al. 2010). 
 
• The classical subtype is the most prevalent and typical form of SCC (36% of all lung SCC). 
It has the highest incidence in male smokers and is characterized by alterations in KEAP1, 
NFE2L2 and PTEN, as well as the greatest overexpression of the three known oncogenes on 
chromosome 3q: SOX2, TP63 and PIK3CA (Hammerman et al. 2012). The classical 
subtype generally overexpresses the p63 transcription factor. 
• The primitive type (15% of all lung SCC) is characterized by rapid cell proliferation, poor 
differentiation, and worse overall survival. It is generally enriched for expression of 
proliferation genes such as Minichromosome maintenance 10 (MCM10), E2F transcription 
factor 3 (E2F3), Thymidylate synthetase (TYMS) and Polymerase α1 (POLA1). 
• The basal subtype (25%) is characterized by a well-differentiated phenotype. It is generally 
enriched for expression of proliferation genes such as Minichromosome maintenance 10 
(MCM10), E2F transcription factor 3 (E2F3), Thymidylate synthetase (TYMS) and 
Polymerase α1 (POLA1). 
• The secretory type (24%) shares many features with lung secretory/glandular cells and 
overexpresses genes responsible for mediating immune responses such as Surfactant and 
Mucin 1 (MUC1). 
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In contrast to adenocarcinoma, the frequency of EGFR mutations and the EML-ALK translocation 
are very low in SCC, and mainly reported in Asian and never smoker patients (Lee et al. 2016; Jin 
et al. 2012). On the other hand, many other oncogenic alterations have been described in lung SCC, 
including SOX2 amplification, dysregulation of the KEAP-NFE2L2 pathway, aberrant PI3K 
pathway activity, FGFR1 amplification, and DDR2 mutation (Drilon et al. 2012; Minuti et al. 
2013). None of these are are currently useful in clinical practice. 
 
 
 
Figure 1.3 Driver mutation in Squamous cell carcinoma 
 
Individual markers can aid pathologic differentiation between adenocarcinoma versus squamous 
histology. Adenocarcinomas tend to stain for mucin (Alcian blue/periodic acid Schiff), thyroid 
transcription factor 1 (TTF-1), and cytokeratin. Squamous lung carcinoma, in contrast, may stain 
for tumours protein p63 (p63), S100 calcium-binding protein A7 (S100A7), cytokeratin 5/6, and 
other high molecular weight cytokeratins. 
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1.1.3 SCLC  
SCLC is defined as “a malignant epithelial tumour consisting of small cells with scant cytoplasm, 
ill-defined cell borders, finely granular nuclear chromatin, and absent or inconspicuous nucleoli” 
(Travis et al. 2011). 
From patients with SCLC, about 30% of them, they will have limited-stage disease (LD) (Murray et 
al. 1993). This means that the tumours of these patients are restricted to the hemithorax of origin, 
the mediastinum, or the supraclavicular lymph nodes. When the tumours are spread beyond the 
supraclavicular areas, then these patients have extensive-stage disease (ED). Patients with distant 
metastases are also considered to have ED (Shepherd et al. 2007).  
The most frequently genetic abnormalities in SCLC are inactivation mutations in tumour suppressor 
genes such as TP53 and retinoblastoma gene 1 (RB1); other genetic alterations including 
overexpression of BCL-2 and only infrequent gain-of-function mutations in oncogenes such as 
PI3K3 or MYC family members (D'Amico et al. 1992; Yuan et al. 1999). 
In contrast to other types of lung cancer, molecular markers that help to predict the prognosis or 
guide the choice of therapy in patients with SCLC are still lacking. 
 
 
Figure 1.4 Driver mutation in SCLC 
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1.2 Staging of lung cancer 
All cancers are staged using the international Tumour, Node, Metastasis (TNM) system published 
by the Union for International Cancer Control. These staging guidelines are continuously being 
revised and updated. The T describes the size of the original (primary) tumour and whether it has 
invaded nearby tissue. The N describes nearby (regional) lymph nodes that are involved. The M 
describes distant metastasis (spread of cancer from one part of the body to another). 
 
• Stage I: The cancer is located only in the lungs and has not spread to any lymph nodes. 
 
• Stage II: The cancer is in the lung and nearby lymph nodes. 
 
• Stage III: Cancer is found in the lung and in the lymph nodes in the middle of the chest, also 
described as locally advanced disease. Stage III has two subtypes: 
 
If the cancer has spread only to lymph nodes on the same side of the chest where the cancer 
started, it is called stage IIIA. 
 
If the cancer has spread to the lymph nodes on the opposite side of the chest, or above the collar 
bone, it is called stage IIIB. 
 
• Stage IV: This is the most advanced stage of lung cancer, and is also described as advanced 
disease. This is when the cancer has spread to both lungs, to fluid in the area around the 
lungs, or to another part of the body, such as the liver or other organs. 
 
 
 
 
 
 
 
 
 
 
 
! 13!
1.3 Therapy in lung cancer 
Most stage I and stage II non-small cell lung cancers are treated with surgery to remove the tumour. 
Surgery is the recommended treatment for patients with stage I–II non-small-cell lung cancer 
(NSCLC) (Vansteenkiste et al. 2014). 5-year survival is 77–92% for clinical stage IA, 68% for stage 
IB, 60% for stage IIA, and 53% for stage IIB. By pathological stage, 5-year survival is 80–90% for 
stage IA, 73% for stage IB, 65% for stage IIA, and 56% for stage IIB (Goldstraw et al. 2016). 
Treatment for stage IIIA NSCLC may include some combination of radiation therapy, 
chemotherapy (chemo), and/or surgery. For this reason, planning treatment for stage IIIA NSCLC 
often requires input from a medical oncologist, radiation oncologist, and a thoracic surgeon. Stage 
IIIB NSCLC has spread to lymph nodes that are near the other lung or in the neck, and may also 
have grown into important structures in the chest. These cancers cannot be removed completely by 
surgery. As with other stages of lung cancer, treatment depends on the patient’s overall health. In 
stage IV lung cancer, chemotherapy is typically the main treatment and radiation is used only for 
palliation of symptoms. Until the mid-2000’s, treatment options were mostly limited to surgery, 
chemotherapy and radiation. Now, people diagnosed with lung cancer often have newer, more 
personalized treatment options. 
 
EGFR mutations 
The epidermal growth factor receptor (EGFR, HER-1/ErbB1) is a receptor tyrosine kinase (TK) of 
the ErbB family, which consists of four closely related receptors: HER-1/ErbB1, HER-
2/neu/ErbB2, HER-3/ErbB3 and HER-4/ErbB4. 
Epidermal growth factor receptor inhibitors can block the signal from EGFR that tells the cells to 
grow. Some of these drugs can be used to treat NSCLC. EGFR inhibitors used in NSCLC with 
EGFR gene mutations: Erlotinib (Tarceva™), Afatinib (Gilotrif™), Gefitinib (Iressa™). EGFR 
inhibitors can often shrink tumors for several months or more. But, eventually, these drugs stop 
working for most people, usually because the cancer cells develop another mutation in the EGFR 
gene. How this acquired resistance towards tyrosine kinase inhibitors occurs is not fully understood, 
but secondary mutations in EGFR and amplification of the oncogene MET are common in these 
patients. The most common secondary EGFR mutation is the substitution of methionine for 
threonine at position 790 (T790M) (Balak et al. 2006). Osimertinib therapy is the current standard 
of care for patients with EGFR mutation-positive NSCLC who develop EGFR T790M after prior 
EGFR-TKI therapy. Mechanisms of resistance to osimertinib therapy have also been reported. In a 
preclinical cell line study, acquired EGFR C797S mutation (the substitution of cysteine with serine 
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at amino acid position 797, EGFR C797S) was identified as a mechanism of resistance to 
osimertinib therapy. 
Other mechanisms of resistance to osimertinib therapy have also been identified in cell line studies, 
including NRAS E63K mutation and gains of copy number for wild-type NRAS and wild-type 
KRAS (Liao et al. 2016) 
 
ALK translocation 
The first evidence of differences between anaplastic lymphoma kinase (ALK) gene-echinoderm 
microtubule-associated protein-like 4 (EML4) translocated and wild-type counterparts lung tumours 
arose in 2007 (Soda et al. 2007). 
Crizotinib is a first generation multi tyrosine kinases inhibitor of ALK, MET, and ROS1 that 
demonstrated a meaningful activity on ALK positive NSCLCs. In the earliest experiences with 
crizotinib in advanced and heavily pretreated NSCLC ALK positive patients, this drug showed an 
impressive response rate achieved in approximately 60% of patients with a median PFS of 7–10 
months (Kwak et al. 2010; Camidge et al. 2012; Kim et al. 2012). Given these promising results, 
crizotinib obtained US Food and Drug Administration (FDA) approval in 2011, specifically in ALK 
positive patients using the Vysis ALK Break-Apart FISH Probe Kit (Abbott Molecular, Inc.). 
Within the first years after treatment with crizotinib, resistance could occur. Some biologic 
mechanisms could explain the drug resistance, like secondary mutations and copy number gain in 
the ALK gene; activation of the bypass tracks, including EGFR, KRAS, KIT, MET, and IGF-1R 
(Toyokawa and Seto 2015). However, different ALK inhibitors have been recently developed, like 
alectinib, ceritinib, brigatinib (AP26113), and lorlatinib. 
 
KRAS mutations 
The most common KRAS mutation are missense substitutions in codons 12, 13, or 61. These 
mutations result in a constitutively active RAS due to malfunctioning of the RAS GTPase. 
In general, the presence of KRAS mutation excludes EGFR mutation or ALK translocation. It is not 
druggable, so one way to inhibit KRAS is to use the inhibition of its downstream pathway, like 
MEK inhibition (Janne et al. 2013). 
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ROS1 translocation 
ROS1 fusion is the product of chromosomal rearrangement of ROS1 gene. It is identified in 
approximately 1% of lung cancers, and it is associated with adenocarcinoma histology, and is 
typically observed in younger patients and those who have never smoked. OS1 receptor has a TK 
domain; its activation provokes cell growth and proliferation. Kinase receptor of ALK and ROS1 is 
similar, so they can be blocked with the same drugs (Cortinovis et al. 2016). 
 
C-MET amplification 
The MET proto-oncogene encodes for the receptor tyrosine kinase (RTK), c-MET. Cells of 
epithelial–endothelial origin widely express c-MET, where it is essential for embryonic 
development (Brand-Saberi et al. 1996; Heymann et al. 1996; Bladt et al. 1995) and tissue repair 
(Borowiak et al. 2004). Because of its pleotrophic role in cellular processes important in 
oncogenesis and cancer progression, c-MET is considered to be an important target in anticancer 
therapy (Trusolino et al. 2010). Several molecules targeting c-MET have recently been evaluated in 
early phase clinical trials. Most of them are small kinase inhibitors, while some are biological 
antagonists and monoclonal antibodies targeting either the ligand or the receptor (Eder et al. 2009; 
Comoglio et al. 2008;). 
 
DDR2 mutation 
The DDR2 gene encodes a cell surface RTK that is mutated to an active form in about 4% of 
squamous cell carcinomas of the lung (Heist et al. 2012). Dasatinib inhibits DDR2, and one patient 
treated with the combination of dasatinib and erlotinib had a tumour response. Clinical trials to 
determine dasatinib efficacies are underway. 
 
HER2  
Human epidermal growth factor receptor 2 (HER2) is a member of the ERBB receptor tyrosine 
kinase family. Binding of ligand leads to dimerisation and activation of HER2 TK activity. 
Activated HER2 then phosphorylates its substrates leading to the activation of multiple downstream 
pathways including PI3K-AKT-mTOR and RAS-RAF-MEK-ERK pathways. NSCLC, 
amplification of HER2 detected by FISH is found in 2%–4% of NSCLC patients. HER2 
overexpression by immunohistochemistry is detected in 13%–20% of NSCLC samples, although 
strong expression is only found in 2%–4% (Hirsch et al. 2002; Heinmoller et al. 2003). About 1%–
2% of adenocarcinoma patients harbor mutations in the exon 20 of HER2 (Arcila et al. 2012;  
Stephens et al. 2004). Although commonly found in never smokers with adenocarcinoma, HER2 
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mutations are also reported in other subsets of NSCLC (Buttitta et al. 2006). HER2 amplification is 
a negative prognostic marker as shown in a recent meta-analysis (Liu et al. 2010). Preclinical data 
suggests that the presence of HER2 mutation is associated with primary resistance to the first 
generation EGFR TKIs, erlotinib, and gefitinib. However, cells expressing the HER2 exon 20 
mutation are sensitive to the irreversible dual EGFR and HER2 TKIs, lapatinib, neratinib, and 
afatinib (Wang et al. 2006; Li et al. 2008). 
 
BRAF mutation 
BRAF (v-Raf murine sarcoma viral oncogene homolog B) is a serine-threonine kinase belonging to 
the RAF kinase family lying downstream of KRAS and directly interacting with the MEK-ERK 
signaling cascade. In lung adenocarcinoma BRAF mutations are found in 1%–5%, half of them 
harboring the classical V600E mutation (Naoki et al. 2002; Marchetti et al. 2011). Unlike 
melanoma, NSCLCs mostly harbor non- Val600Glu mutations including the Leu596Val mutation 
in the kinase domain (Davies et al. 2002; Sasaki et al. 2006; Naoki et al. 2002). The various BRAF 
mutations observed in NSCLC are as follows: G466V, G469A, L597V and V600E. BRAF 
mutations are mutually exclusive to EGFR and KRAS mutations and have been associated with 
decreased sensitivity to the EGFR TKI, gefitinib (Gandhi et al. 2009). BRAF V600E mutations are 
associated with light/never smoker status, micropapillary histology and occur more frequently in 
female patients. In contrary, non-V600E mutations are more frequent in former or current smokers 
and are associated with poorer outcome (Marchetti et al. 2001; Paik et al. 2011). Multiple BRAF 
inhibitors like PLX4032 (molecular inhibitor selective for BRAF), sorafenib (a multikinase 
inhibitor of RAF-1, BRAF, VEGF, and PDGF), and CI-1040 (a first-generation-specific inhibitor of 
MAP kinase) are currently under development. 
 
Often, targeted therapies work well for a period of time, but then stop working (the cancer develops 
“resistance”). This is more common with some drugs than others. Principal mechanisms of 
chemoresistance include: altered membrane transport involving the P-glycoprotein product of the 
multidrug resistance (MDR) gene as well as other associated proteins; altered target enzyme (e.g. 
mutated topoisomerase II); decreased drug activation; increased nuclear receptor activation; 
increased drug metabolism and elimination due to altered expression of cytochrome P450 enzymes; 
drug inactivation due to conjugation with increased glutathione; subcellular redistribution; drug 
interaction; enhanced DNA repair and failure to apoptose as a result of mutated cell cycle proteins 
such as p53.  
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Immunotherapy 
Immunotherapy has long been considered the holy grail of Oncology. Different attempts have been 
made to harness body’s immune system to eradicate malignancy. Immunotherapeutic approaches 
are based on the premise that the immune system plays a key role in surveillance and the 
eradication of malignancy, and tumours evolve in order to elude the immune system.  
Lung cancer has the second highest mutation burden after melanoma, which increases its 
susceptibility to immunotherapy (Alexandrov et al. 2013). 
Several monoclonal antibodies directed to the PD-1 receptor (nivolumab, pembrolizumab) or its 
ligand PD-L1 (atezolizumab, durvalumab, avelumab) have reached the clinic, and others are in 
preclinical development. Nivolumab is a fully human IgG4 immune checkpoint inhibitory antibody, 
which binds to PD-1, preventing its interaction with its ligands PD-L1 (also called B7-H1 or 
CD274) and PD-L2 (also called B7-DC or CD273). 
Different approaches have been taken to PD-L1 IHC assessment, using different diagnostic 
antibodies to assess PD-L1 expression, different technical staining platforms, and different 
definitions of a “positive” predictive IHC stain. In some cases, expression of PD-L1 on immune 
effector cells as opposed to, or in combination with, expression in tumour cell has been chosen as 
biomarker. There is variable interpretation of the intensity and distribution of staining and variable 
definition of a positive PD-L1 stain ranging from staining of ≥1% to ≥50% of cells assessed. In 
some cases, the test requires at least 100 tumour cells to be assessed (Kerr et al. 2015). 
Regarding the assay itself, the influences of preanalytical variables, applicability across different 
staining platforms, usage on different sample types (large tumor samples, small biopsies, and 
cytology), intralaboratory and interlaboratory reproducibility, intraobserver and interobserver 
variability, and epitope stability in stored materials are matters for further study (Kerr et al. 2015). 
 
1.4 Genetics of lung cancer 
The aberrant activation of multiple signal pathways, such as RAS/RAF/MEK, PI3K/AKT/mTOR 
and STAT leads to the uncontrolled growth of cancer and impaired cell death signalling.  
The PI3K/AKT/mTOR signalling pathway is involved in the survival, proliferation, and migration 
of SCLC and NSCLC (Wojtalla et al. 2013, Tsurutani et al. 2006). The PI3K/AKT/mTOR 
signalling pathway may be activated in cancer through multiple mechanisms including mutations in 
PIK3CA, which encodes the catalytic subunit of PI3K, loss or mutation of phosphatase and tensin 
homolog (PTEN), AKT mutations and deregulation of mammalian target of rapamycin (mTOR) 
complexes (Samuels et al., 2004). 
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Umemura et al. (2014) found in about 50 SCLC cases a higher penetrance of activating alterations 
of the PI3K/AKT/mTOR pathway that act in a mutually exclusive manner. One cause of therapeutic 
resistance is inactivation of cancer suppressor PTEN, which allows over-activation of the 
PTEN/PI3K/AKT pathway. Evidence has shown that the poor prognosis of patients with NSCLC of 
all stages and therapeutic failure are associated with a number of abnormally activated signalling 
PI3K/AKT pathway, and this is more common in SCC than in AD (Drilon et al. 2012). 
The major characteristics of malignant tumour cells are their ability to invade foreign tissues and 
form metastatic foci at distant locations in the body. Such processes require tumour cell attachment 
to various matrix proteins and the degradation of the extracellular matrix (ECM), mainly by matrix 
metalloproteinase (MMP) that may facilitate tumour invasion, metastasis and angiogenesis. 
Increased levels of MMPs have been detected in numerous cancers and were correlated with tumour 
aggressiveness (Shuman Moss et al. 2012). For example, MMP-1, −2, −7, −9, −14, and −15 were 
overexpressed in NSCLC (Leinonen et al. 2006; Shah et al. 2010; Stenvold et al. 2012), and 
elevated MMP-1, −9, −11, −13, and −14 levels were also shown in SCLC (Michael et al. 1999; 
Rintoul et al. 2001). The TIMP3 and RECK has an inhibitory effect on tumour metastasis due to its 
interaction with MMPs. A clinical study showed that the expression of TIMP-3 was reduced in a 
number of cancer types and reduced expression of TIMP-3 was significantly associated with 
pathologic stage, nodal involvement, and poor survival in lung cancer patients. RECK (reversion-
inducing cysteine-rich protein with Kazal motifs) is a membrane anchored glycoprotein which 
regulates MMPs and inhibits angiogenesis. Recent analyses indicate that RECK expression is 
frequently down-regulated in tumour tissues in comparison with the surrounding non-tumours 
tissues in several common types of cancer including colon, mammary, pancreatic carcinoma and 
lung cancer (Noda et al. 2003; Pesta et al. 2009). 
DNA damages give rise to mutations and epimutations that, by a process of natural selection, can 
cause progression to cancer. If DNA damages in proliferating cells are not repaired due to 
inadequate expression of a DNA repair gene, this increases the risk of cancer. Many known 
carcinogenic agents cause reduced expression of DNA repair genes or directly inhibit the actions of 
DNA repair proteins.   
The NER system is essential for repairing DNA damage such as pyrimidine dimers, cross-links, and 
bulky adducts induced by platinum chemotherapy. Excision repair cross-complementation group 1 
(ERCC1) is one of polypeptides of the nucleotide excision repair (NER) system. ERCC1 plays a 
pivotal role in DNA repair by removal of DNA-platinum adduct, which inhibits DNA synthesis in 
cancer cells. Some gene expression of markers of sensitivity to specific cytotoxic agents, such as 
thymidylate synthase (TYMS) and dihydrofolate reductase (DHFR), enzyme that plays an important 
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role in DNA synthesis. In NSCLC, overexpression of TYMS is associated with poor prognosis 
following lung resection and low TYMS mRNA level is associated with better response to 
neoadjuvant pemetrexed/gemcitabine treatment (Liu et al. 2015). 
 
1.5 Epigenetics  
Epigenetics consists of heritable modifications to the chromatin that influence gene expression and 
other DNA- dependent processes without directly altering the DNA coding sequence (Holliday 
1987). Mutations in epigenetic regulatory mechanisms and epigenetic pattern perturbations are 
implicated in many tumor types, including lung cancer, occurring through tumor suppressor gene 
silencing and oncogene activation (Jones and Baylin 2002). These complex processes involve DNA 
methylation, microRNA (miRNAs) regulation, and histone/ nucleosome modifications.  
During the last 15 years, miRNAs have been in the limelight of human genetics due to their 
involvement in the development of several pathologies, particularly cancers. MiRNAs are a class of 
evolutionarily conserved, small non-coding RNAs of 19-24 nucleotides in length that regulate gene 
expression mostly at the posttranscriptional level (Bartel 2009). Public database, miRBase 
(http://www.mirbase.org/) (last access: XX Gennaio 2017) provides various aspects of microRNA 
information, and the annotated human microRNAs of 1881 have been registered in miRBase 21. 
 
1.5.1 Biogenesis of miRNA 
The biosynthesis of miRNAs is a tightly regulated multistep process that starts in the nucleus of the 
cell, following transcription, and continues through the cytoplasm where finally the mature miRNA 
molecule exerts its main function. 
Briefly, the biogenesis of miRNAs starts with their transcription by RNA polymerase II although 
some other miRNAs are transcribed by RNA polymerase III (Borchert et al. 2006) resulting in a 
primary transcript known as pri-miRNA. A typical pri-miRNA consists of a stem of 33–35 bp, a 
terminal loop and single-stranded RNA segments at both the 5  ʹand 3  ʹsides. The nuclear RNase III 
Drosha initiates miRNA processing. This stem-loop structure is recognized by Drosha as part of a 
microprocessor complex in conjunction with a dsRNA-binding protein DGCR8. Drosha cleaves the 
pri-miRNA at the base of the stem-loop, releasing it from the flanking single-stranded regions. 
Cleavage of both arms of the stem-loop is dependent on the tandem RNase III domains of Drosha 
binding and cleaving the dsRNA stem. The released stem-loop structure is exported from the 
nucleus by exportin 5 and is known as a pre-miRNA. Once, in the cytoplasm, a second RNase III, 
Dicer, together with its dsRBD protein partner, the trans-activator RNA (tar)-binding protein 
(TRBP) makes a pair of cuts that defines the other end of the mature miRNA, liberating an 21-
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nucleotide RNA duplex. Double stranded mRNA is generally a transient imperfect duplex molecule 
consisting of a passenger strand and a mature microRNA strand (also referred to as guide strand) 
commonly denoted miRNA:miRNA*, where the passenger strand is designated miRNA*. One of 
the strands of the miRNA duplex is incorporated into an Argonaute (Ago) protein, forming the 
minimal effector RNA induced silencing complex (miRISC). miRISC is the cytoplasmic effector 
machine of the miRNA pathway and contains a single-stranded miRNA guiding it to its target 
mRNAs. Activated miRISC binds target mRNA through Watson-Crick base-pairing between the 
guide strand and the 3’UTR of the target . This binding of miRISC leads, dependent on the degree 
of miRNA complementarity, to the inhibition of mRNA translation, or mRNA cleavage and 
subsequent degradation (Lin and Gregory 2015)(figure 1.5).  
 
 
 
Figure 1.5 Biogenesis of miRNAs 
 
 
1.5.2 Genomic Organization of miRNAs 
MiRNAs sequences are distributed all throughout the genome, being localized in exonic or intronic 
regions, as well as intergenic locations (Altuvia et al. 2005).  
According to a recent annotation of known and novel miRNAs, most of the known miRNAs map to 
intergenic regions (~70%) and introns (~12%). Smaller proportions map to repeat regions (~8%), 
exons (~5%), and long noncoding transcripts (~5%) (Londin et al. 2015). In human, there are 
almost equal numbers of known intergenic and intragenic miRNA genes (Paczynska et al., 2015). 
Furthermore, while some miRNA genes are located far from other miRNA loci, others are located 
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proximal to each other and are thought to be described in clusters (Altuvia et al., 2005). Clustered 
miRNAs are transcribed as polycystronic RNAs by polymerase II, while other miRNAs are 
transcribed as monocystronic miRNAs. There are usually two or three genes per cluster and the 
largest cluster, at 13q31 (miR-17-92 cluster), is composed of seven (miR-17-5p, miR-17-3p, miR-
18a, miR-19a, miR-20a, miR-19b and miR-92-1) (Calin et al. 2002; He et al. 2005). In humans 
approximately 50% of known human miRNAs are found in clusters and they are transcribed as 
polycistronic primary transcripts (Lagos-Quintana et al. 2001; Lau et al. 2001). This genomic 
organization confers simultaneous expression of similar miRNAs, possibly leading to a synergistic 
effect in their ultimate function. 
 
1.5.3 Biomarkers 
Initially, miRNAs were thought to be involved in the regulation of development and cell fate, but 
more recently it has been discovered that miRNAs partecipate in a broad range of processes 
including cell cycling, apoptosis, cell differentiation, tumour development, invasion, metastasis, and 
angiogenesis (Friedman et al. 2009). In particular, miRNAs have been observed to be aberrantly 
expressed in many human cancers (Cortez et al. 2011) and they are promising alternative 
biomarkers for detecting cancer, establishing prognosis, and monitoring treatment response, as well 
as crucial players in cancer initiation, development and metastasis (Cortez et al. 2011). The possible 
applications of miRNAs in molecular prognostics, particularly in cancer, are provided by discovery 
of the role of miRNA in many pathological processes, and for cancer prognosis; miRNA can be 
complementary to other genomic and proteomic biomarkers (Cho 2007). From the biological point 
of view, miRNAs may be better predictive and prognostic markers than DNA or mRNA. A single 
miRNA, indeed, may regulate hundreds of target mRNAs, frequently grouped in a specific 
biological pathway. Consequently, a miRNA signature may provide comparable prognostic 
information several orders of magnitude greater than mRNAs.  
Besides miRNAs are more stable than other biomarkers during sample processing, thus more 
suitable for analysis in plasma, urine, stool and tissue (fresh or FFPE - Formalin-fixed, paraffin-
embedded) sample and this is a key point in the search for cancer markers. 
However, the underlying mechanisms of miRNA deregulation in human cancer are still not 
thoroughly understood. Increasing evidence indicates that transcriptional deregulations, epigenetic 
alterations, mutations, DNA copy number abnormalities and defects in the miRNA biogenesis 
machinery might be the possible mechanisms, these mechanisms may each contribute, either alone 
or more likely together to miRNA deregulation in human cancer (Deng et al. 2008). Deregulation of 
enzymes and cofactors involved in biogenesis pathways can affect the levels of mature miRNAs 
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and have important biological ramifications. For example, deletion of a single Dicer1 allele in lung 
epithelia promotes Kras-driven lung adenocarcinomas, whereas complete ablation of Dicer1 causes 
lethality because of the need for miRNAs in essential processes (Kumar et al. 2009). In addition, 
global repression of miRNA biogenesis by suppression of the key components of miRNA 
processing machinery, such as Drosha, DGCR8, Dicer, TRBP, and XPO5, promotes cellular 
transformation and tumorigenesis (Melo 2009 and 2010, Chang 2008, Kumar 2007). 
Several recent studies have demonstrated how oncogenic miRNAs may interfere with DNA-repair 
pathways allowing cells to resist drugs that initially were effective against them (Giovannetti et al. 
2012).  To restore drug sensitivity via miRNAs, potential approaches include activation of tumour 
suppressor miRNAs or inactivation of oncogenic miRNAs and modulation of miRNA target genes, 
oncogenes, and tumour suppressor genes, through up- or down-regulation of miRNAs (Sarkar et al. 
2010; Giovannetti et al. 2012).  
Recent studies have indicated an emerging role for miRNAs, in addition to genetic and epigenetic 
changes (methylation/acetylation), in the anticancer-drug-resistant phenotype (Giovannetti et al. 
2012), which opens up the possible application of miRNAs in evaluation of outcome and 
modification of response in known anti-tumour therapies (Hummel et al. 2010). The discovery of 
the roles of miRNAs in carcinogenesis has propelled miRNAs to become focal targets for novel 
therapeutic approaches, and efforts have been made in recent years to develop miRNA-based 
therapeutics. We could suppose that miRNAs will be the future targets of molecular-based drugs, as 
demonstrated by MRX34, the first mimic-miRNA that enters in a phase I clinical trial for the 
treatment of liver cancer (Paloma et al. 2015). 
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Figure 1.6 Clinical applications of miRNAs 
 
 
1.5.4 Biomarkers Lung Cancer 
The growing number of studies examining the global changes in miRNA expression and those 
focusing on the role of specific individual miRNAs in lung tumors suggests that these molecules 
may play a role in the pathogenesis of lung cancer and serve as biomarkers for the diagnosis and 
prognosis of diseases. 
A number of studies have shown that miRNAs are differentially secreted into the serum or blood of 
lung cancer patients (Chen et al. 2008; Hu et al. 2010). Since the first report of miRNA deregulation 
expression in cancers (Calin et al. 2002), these small RNAs are now recognized to be key regulators 
for tumor pathogenesis and markers for novel clinical interventions. A major oncogenic miRNA in 
lung cancer is the miR-17~92 cluster. The expression of miR-17~92 is subject to transactivation by 
E2F family members (Sylvestre et al. 2007) and MYC (O'Donnell et al. 2005) with the latter 
frequently overexpressed in SCLC (Takahashi et al. 1989). 
Hsa-let-7 was the first miRNA reported to play a role in the development and progression of lung 
cancer. Reduced hsa-let-7 expression in NSCLC patients was significantly associated with 
shortened postoperative survival, independent of disease stage (Takamizawa et al. 2004).  
Another study showed that high expression of miRNA-146b and miRNA-155 in lung SCC and 
adenocarcinoma, respectively, was associated with poor OS of the patients after surgical resection 
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of the tumour (Raponi et al. 2009; Yanaihara et al. 2006). miRNA expression profiling of formalin-
fixed, paraffin-embedded (FFPE) NSCLC tumors of stage I-III has shown that miRNA-221, 137, 
372, 182* and let-7a have prognostic value (Yu et al. 2008). 
Generating miRNA signatures and classifiers can point basic researchers towards targets for 
investigations that can maximize the usefulness of information concerning diagnostic and 
chemotherapeutic outcomes in NSCLC patients. 
Finally, there are very few studies dealing with the feasibility of the expression of miRNA on 
cytological samples, following the report of two examples. Fassina et al. develop a miRNA 
expression method for differentiating AD from SCC in cytologic specimens obtained by means of 
such a minimally invasive and safe technique as CT-guided TTNA (Fassina et al. 2011). Gilad et al. 
develop an assay based only of the expression of a small set of miRNAs that may help to 
differentiate the four main types of lung cancer. The assay displays high levels of accuracy in 
pathologic and cytologic samples. For the latter, fine-needle aspiration (FNA) and bronchial 
brushing and washing samples were tested, demonstrating the versatility of the assay (Gilad et al. 
2012). 
In light of these results, we selected three miRNA that were previously reported to be involved in 
processes or pathways that have been associated with a prognostic and predictive role, namely 
PI3K/AKT/mTOR pathway (miR-192; miR-200c, miR-205), regulation of MMPs expression (miR-
200c, miR-205) and DNA damages/repair (miR-192).  
 
1.6 Focus on SCLC 
the diagnosis of SCLC could be suspected on the basis of clinical presentation and imaging studies 
but pathologic confirm is required. Cytology from bronchoscopy or from fine-needle aspirations 
(FNAs) are often the preferred approaches in order to achieve the diagnosis, either from primary 
tumor or from metastasis because of the minimal trauma to the patient and ease of sample 
acquisition. Cytologic diagnosis needs to be confirmed by immunohistochemistry for several 
markers like cytokeratins, TTF-1, chromogranin, synaptophysin or CD56, that can be performed on 
cell blocks or on direct smears. 
The prognosis for patients with SCLC is poor, with a median survival of 4 to 12 months depending 
on the stage of their disease. The best prognostic factors include limited-stage disease (LD) (TNM 
stages I-III), age less than 70 years, female sex, performance status (ECOG/WHO) less than 1 and 
normal baseline concentrations of LDH, sodium, alkaline phosphatase, and bicarbonate in serum.  
Recently, panels of miRNAs have been proposed as promising markers useful to predict 
chemoresistance and prognosis in non-SCLC treated with systemic chemotherapy. In another study, 
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miRNA microarray analysis was performed in order to identify unique signature profile helpful to 
predict survival and chemoresistance also in SCLC, with promising results. 
However, main limitations of the microarray technology are lower specificity and sensitivity 
compared with qRT-PCR and the difficulty to perform the analysis in routine clinical setting. 
The first end-point of our study was to evaluate whether miRNA expression analysis could be 
feasible also in cytological specimens with various fixation methods, and therefore potentially 
applicable to routine samples. 
 
1.7 Focus on SCC 
Prognostic factors for SCC have been mostly derived from surgically resected tumors in patients 
with early-stage disease.  
SCC of the lung is separated as a unique clinical and histologic category of NSCLC. In general, 
SCCs tend to be locally aggressive with metastasis to distant organs occurring less frequently than 
in adenocarcinomas of the lung (Drilon 2012).  Immunohistochemical (IHC) analysis for both P63 
and TTF1 has been established as an effective approach to determine lineage in morphologically 
challenging situations (Travis et al. 2011); SCC consistently express P63 and are negative for 
TTF1. Even when surgery and other therapies are initially successful, SCC can return. This is 
because cancer cells can start to spread without being detected right away. Increasing evidence 
suggests that SCC and adenocarcinoma of the lung are molecularly two separate entities 
(McDoniels-Silvers et al. 2002). However, in contrast to lung adenocarcinoma, still now no 
approved targeted therapies are available for SCC. The targeted drugs developed for lung 
adenocarcinoma such as EGFR tyrosine kinase inhibitor (EGFR-TKI) and ALK inhibitor, are 
largely ineffective against SCC. In view of the high rate of relapse and the lack of predictive 
biomarkers, it is critical to develop biomarkers that can identify high-risk early stage of desease and 
a new therapeutic strategy is required for patients with resectable SCCs. 
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2. OBJECTIVES OF THE THESIS 
 
A) SCLC 
Since most of the SCLCs are yet diagnosed in cytologic samples or in small biopsies, often 
containing a limited number of neoplastic cells, the first objective was the evaluation of the 
feasibility of miRNA extraction in clinical samples, after their use for immunohistochemistry 
analysis, and the possible influence of the different types of fixative solution in the preservation of 
the integrity of miRNA. Moreover, we tried to identify a panel of miRNAs possibly useful in 
clinical practice as prognostic and /or predictive biomarkers. 
 
B) SCC 
In this subset of lung cancers, our project was addressed to search for the useful of the same 
miRNA panel used for SCLC, as prognostic biomarker in operable tumors, by comparing the 
different level of expression of  N0 tumors vs N+ tumors in stage I II and III. 
!
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3. MATERIAL AND METHODS 
 
3.1 Patients and Samples of SCLC 
Cytologic samples from 50 consecutive patients with SCLC were collected from the archives of 
Pathology Unit of University Hospital of Novara between January 2006 and December 2014.  
Twenty-five samples (50%) were from primary tumours and 25 from metastatic regional lymph 
nodes. Forty-four samples (88%) were obtained by fine needle aspirations (FNAs), and six (12%)  
by bronchial washing (BWs). 
FNAs were performed using 21 or 22-gauge disposable needles, immediately smeared onto a glass 
slide and spray-fixed using ethanol (Bio-Fix, Bio Optica, Milan, Italy). Part of the needle content 
was also washed in lysing solution and centrifuged at 1,800 g to obtain cell blocks. They were 
prepared using agarose gel and fixed in ethanol. 
Specimens from bronchial washing were centrifuged to obtain a cell pellet, then the pellet was 
partially smeared onto a glass slide and spray-fixed, whereas the remaining part was fixed with  
Duboscq-Brazil fluid for 24 hours; afterward, paraffin-embedded cell blocks were prepared and 
sectioned. Specimens from slide obtained by transferring smear to glass slide were stained with the 
Papanicolaou stain and permanently mounted. The sections obtained by cutting paraffin-embedded 
cell blocks, were stained by haematoxylin-eosin and by immunohistochemistry to define the 
diagnosis of SCLC. A panel of immunohistochemistry was used in all the cases and included the 
following antibodies: synaptophysin, CD56, chromogranin, and CK AE1/AE3 (Ventana Medical 
System, Tucson, AZ). The reactions were performed by means of Benchmark instruments (Ventana 
Medical System). 
Ten normal lung tissue samples obtained from surgical resection of lung carcinoma were selected 
after light microscopy examination and used as positive controls. 
 
3.1.1 RNA Isolation in SCLC 
Total RNA from cell blocks and papanicolaou-stained smear slide was extracted using 
RecoverAllTM Total Nucleic Acid Isolation Kit (Life TechnologiesTM). 
An alternative method of microdissection was set-up with a higher yield and it turned up to be more 
accurate to extract RNA from neoplastic areas, discriminating between normal cells and necrotic 
areas. A different method consists in this: 3-µm-thick sections were placed on glass slides, ten 
slides for each cellblock. Then, each slide was stained with H&E staining and uncovered. H&E 
staining was performed with Leica ST5020 Multistainer, and the program was set as follows: 4 
times in ovens/slide drying stations for 5 minute at 62°C, xylene for 3 minute x 3, absolute (100%) 
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ethanol  for 2 minute x 2, ethanol 95%  for 1 minute, water for 4 minute, Mayer's hemalum for 10 
minute, water for 8 minute, eosin for 1 minute, water for 10 second, ethanol 95%  for 40 second, 
absolute ethanol  for 2 minute x 2, xylene for 4 minute. 
Throughout microdissection, it was necessary to use absolute ethanol with the aid of a modified 
pipette-needle, to prevent the loss of material (due to electrostatic phenomena during sample 
collection). This device consists of a 22-gauge-needle inserted in a Pasteur pipette and wrapped 
with parafilm in order to maintain an airtight seal between the two devices (figure 3.1 A). All glass 
slides samples were observed with a microscope Eclipse 80i (Nikon) with magnification of 10X. 
RNA detection was performed from uncovered stained slides by collecting tumour cells with 
modified pipette-needle and absolute ethanol (figure 3.1 B). The specimen soaking in absolute 
ethanol was transferred into a 1.5 mL tube, made up to 1 mL with ethanol and centrifuged at 14.000 
rpm for 7 min. Then, supernatant was carefully discharged and the pellet was retained. The pellet 
was dried in Concentrator 5301 (Eppendorf) at 30°C for 45 minute. Thereafter, manufacturer's 
instructions of RecoverAllTM Total Nucleic Acid Isolation Kit (Life TechnologiesTM) were 
followed by Protease Digestion to the Final Nucleic Acid Purification. RNA purity and 
concentration were determined by NanoDrop. 
 
 A 
  B1       B2 
 
Figure 3.1. A) Modified pipette-needle: 22-gauge-needle inserted in a Pasteur pipette and wrapped 
with parafilm; B) slide stained with H&E staining and uncovered B1) before collecting tumour cells 
and B2) after collecting tumour cells. 
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3.2 Patients and Samples in SCC of lung 
A total of 86 formalin-fixed paraffin-embedded (FFPE) surgical samples of patients with lung SCC 
were collected retrospectively from the archives of Pathology Unit of University Hospital of Novara 
between February 2009 and December 2012.  
The following eligibility criteria were used: stage I to III at diagnosis; complete resection of the 
primary lung tumor; no treatment with chemotherapy or radiotherapy before surgery; absence of 
cancer within the 5 years before surgery. In all the cases, the morphologic diagnosis was confirmed 
by immunohistochemistry (p40 and/or p63 positivity). Tumor stage was determined according to 
the 2009 TNM staging classification system. Hematoxylin-Eosin (H&E) slides were reviewed by an 
expert pathologist who marked the tumor area without necrosis and with more than 50% of tumor 
cells. Furthermore, 10 normal lung tissue samples obtained from surgical resection of non-
neoplastic diseases, were selected after light microscopy examination and used as control.  
 
3.2.1 RNA Isolation in SCC of lung 
Total RNA containing small RNA was extracted from FFPE of SCC patients and from normal lung 
tissue using RecoverAllTM Total Nucleic Acid Isolation Kit (Life TechnologiesTM, USA). 
Briefly, FFPE tissues were cut into 4–5 sections of 5-µm thickness. Tumor tissues and normal 
tissues were carefully macro-dissected from section slides using a scalpel and transferred into a 
sterile 1.5-ml centrifuge tube. Thereafter, the samples were deparaffinized and extracted according 
to the manufacturer's instructions. RNA purity and concentration were determined by 
Spectrophotometer NanoDrop 2000c (Thermo Scientific, USA). 
 
3.3 cDNA synthesis and miRNA expression analysis by quantitative real-time PCR in SCLC 
and  SCC of lung 
Complementary DNA (cDNA) was synthesised using the TaqMan® MicroRNA Reverse 
Trancription Kit and TaqMan® MicroRNA Assays. For each reverse transcription reaction 50 ng of 
RNA and 3 µL of 5X RT microRNA-specific primers were used in a reaction volume of 15 µL. 
cDNA synthesis was performed by incubation at 16 °C for 30 min, 42 °C for 30 min, 85°C for 5 
min and hold at 4°C. Real-time PCR reaction was performed using 1.40 µL of cDNA, 10 µL 
TaqMan® Fast Universal PCR Master Mix without AmpErase® UNG and 1 µL of primer/probe 
mixture in a total reaction volume of 20 µL. Real-time PCR was performed using the 7500 Fast 
Real Time PCR System (Applied Biosystems, USA) with PCR initial enzyme activation step at 
95°C for 10 min and then 40 cycles of denaturation at 95°C for 15 s and annealing/extension at 
60°C for 1 min. 
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The expression of hsa-miR-192-5p (Assay ID:000491), hsa-miR-200c-3p (Assay ID:002300) and 
hsa-miR-205-5p (Assay ID:000509) was analyzed and RNU6B (U6 snRNA; Assay ID:001093) was 
used as an endogenous control for normalization of expression levels; all TaqMan primer/probe 
were purchased form Applied Biosystems (TaqMan® MicroRNA Assay). Each sample was 
examined in triplicate. 
MiRNA expression levels (relative quantity, RQ) were calculated using the comparative Ct method 
(Livak and Schmittgen, 2001): 2−(ΔCt Tumor – ΔCt Normal Tissues) , ΔCt values were calculated using (Ct 
miRNA – Ct RNU6B) either in tumor and in a pool of normal lung tissues. 
 
3.4 Statistical analysis 
Stata Statistical Software (release 13.0 College Station, Stata Corporation, TX, USA) was used in 
all the statistical analyses. Survival data were analyzed by the Kaplan-Meier method and the 
survival curves were compared by the log-rank test. The variables putatively associated with the 
survival were analyzed by use of univariate Cox proportional hazards regression model. The 
variables selected by the univariate analysis were entered into a multivariate Cox model using a 
forward stepwise elimination algorithm (terms with p > 0.05 were eligible for removal) 
The optimal cut-off point of miRNA espression only for SCC was calculated using the X-Tile. 
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4. RESULTS 
 
4.1 Results of SCLC 
The diagnosis of SCLC was made on the basis of cytologic findings, and immunohistochemical 
positivity for cytokeratin and at least one of the neural markers (i.e. synaptophysin, CD56 or 
chromogranin). Main patients’ demographic and clinicopathologic characteristics are summarised in 
Table 4.1.1. The mean age at diagnosis was 65.8 years (range 34-82 years), 32 patients (64%) were 
male and 18 were female (36%). At the end of the study 43 patients (86%) had died. The median 
overall survival (OS) was 42.4 weeks (range 1.2 to 354.6 weeks). Eighteen patients (36%) had LD 
(III A or III B), whereas 32 patients (64%) had extensive-stage disease (ED) (IV). Twenty-four 
patients (48%) received cisplatin-containing chemotherapy, 13 (26%) were treated with carboplatin-
containing regimens, whereas 13 (26%) received best supportive care only. 
 
Variables Values 
Age (mean±SD) 65.8 ±11.9 
 N° of cases (%) 
Sex  
Male 32 (64) 
Female 18 (36) 
Disease Stage  
         Limited-stage (III A or B) 18 (36) 
         Extensive-stage (IV) 32 (64) 
Chemotherapy  
         Etoposide 27 (54) 
         Irinotecan 10 (20) 
         Other 13 (26) 
Platinum-Based Chemotherapy  
          Cisplatin 24 (48) 
          Carboplatin 13 (26) 
          No 13 (26) 
 
Table 4.1.1. Main Clinicopathologic Characteristics of 50 SCLC Patients 
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4.1.1  Association between single miRNA, selected panel of miRNAs and OS 
All 50 samples had sufficient RNA to perform a miRNA expression profiling of the 3-miRNA 
panel selected for this study (miR-192, miR-200c, miR-205), regardless of sample source and type 
of processing and fixation methods. Mir-192, miR-200c and miR-205 were significantly 
overexpressed (respectively P = .0006; P = .0034; P = .0003) in patients with SCLC than in healthy 
controls. 
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Medians of relative expression levels of each miRNA (miR-192, median 2-ΔΔCt = 13.59; miR-200c, 
median 2-ΔΔCt = 1.81; miR-205, median 2-ΔΔCt  = 2.52) were used as cut-off points in order to divide 
the patients into high (score 1) and low expression (score 0) groups. Subsequently, Kaplan-Meier 
survival curves were generated for the two groups of patients and the difference between the curves 
was assessed by log-rank test. There was no significant difference in OS between the high and low 
expression groups of each single miRNA (miR-192, log-rank P = .362; miR-200c, log-rank P = 
.219; miR-205, log-rank P = .224; data not shown). 
Then, the sum of the previous score of the three miRNAs [i.e. (miR-192 = 1) + (miR-200c=1) + 
(miR-205=1) = 3] was calculated for every patient in order to obtain a cumulative score ranging 
from 0 (level of expression of all miRNAs lower than the median value) to 3 (level of expression of 
all 3 miRNAs higher than the median value). Thereafter, the patients were divided into two groups: 
group A (n=25) with a score 0 or 1 (low-expression miRNA panel), and group B (n=25) with a 
score 2 or 3 (high-expression miRNA panel) (Table 4.1.2).  
Next, we performed a Kaplan-Meier analysis to compare survival between group A and group B, 
and the results showed that patients of group A had a significantly better OS than those of group B 
(P = .029) (Figure 4.1.1). 
 
 
 miRNA N° (%) 
Group A  25 (100) 
   
Score 0 No miRNA ↑ 9 (36) 
   
Score 1 1 miRNA ↑ 16 (64) 
 miR-192 5 (20) 
 miR-200c 8 (32) 
 miR-205 3 (12 ) 
   
Group B  25 (100) 
   
Score 2 2 miRNAs ↑ 16 (64) 
 miR-192 and miR-200c 3 (12) 
 miR-192 and miR-205 8 (32) 
 miR-200c and miR-205 5 (20) 
   
Score 3 3 miRNAs ↑ 9 (36) 
 
Table 4.1.2. Distribution of patients according to different score* 
Abbreviation: ↑, higher than the median expression *score is explained in Methods 
 
 
 
! 33!
 
 
Figure 4.1.1. Survival analysis based on miRNA panel expression. The red line depicts survival curve for 
Group B (high expression profile), and the blue line depicts survival curve for Group A (low expression profile). The 
survival curves were found to be significantly different with a log-rank P .029 
 
4.1.2 Association between miRNA panel, clinical variables and OS 
Clinical variables considered were age at diagnosis and stage of disease. In our cohort, the mean age 
at diagnosis was 65.8 years: the group of patients older than the mean age showed a lower OS than 
the younger patients (Figure 4.1.2 A), although the result was not statistically significant (P = .051). 
As expected, also in our cohort, the patients with LD patients showed significantly better OS than 
ED patients (P = .049) (Figure 4.1.2 B). 
Furthermore, we analysed the association between clinical variables and OS in relation to miRNA 
expression panel (group A and group B), for this reason we divided patients in LD, ED, age less 
than and greater than 65.8 years. We did not find any difference in OS between the group A and the 
group B, and also between LD patients (P = .515) and ED patients (P = .400)  (data not shown).  
Interestingly, in the older patients the OS was significantly better in the group A, than in the group 
B (P = .013; Figure 4.1.3 A); whereas there was no difference in OS between group A and group B 
(P = .407) in the younger patients (Figure 4.1.3 B).  
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Figure 4.1.2. Survival analysis based on mean age and stage of disease. A) The red line depicts survival 
curve for old patients (Age > 65.8), and the blue line depicts survival curve for young patients (Age ≤ 65.8); log-rank P 
= .052; B) The red line depicts survival curve for patients with extensive-stage disease, and the blue line depicts 
survival curve for patients with limited-stage disease; log-rank P = .049. 
 
 
 
 
 
 A                                                                          B 
Figure 4.1.3. Survival analysis based on patients older and younger than 65.8 years and miRNA 
panel. A) Curve for old patients (Age ≥ 65.8); The red line depicts survival curve for the patients of the Group B (high 
expression profile), and the blue line depicts survival curve for the patients of the Group A (low expression profile); 
log-rank P = .013. B) Curve for young patients (Age ≤ 65.8) and miRNA panel, log-rank P = .407. 
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4.1.3 Multivariate analysis 
The variables putatively associated with the survival were individually analyzed by use of 
univariate Cox proportional hazards regression model (Table 4.1.3). 
Significant variables in the univariate analysis (mean age, miR-200c, miR-205, 3-miRNA panel and 
stage) were added to a multivariate model, and backward elimination was applied at the 5% 
significance level. Mean Age (≤ 65.8 years versus > 65.8 years), Stage (LD versus ED) and 3-
miRNA Panel (group A versus group B) were the only significant predictors. 
 
 
Univariate Cox regression HR (95% CI) P 
Sex 1.06 (0.56 – 1.97) .861 
miR-192  1.00 (0.997 – 1.01) .308 
miR-200c 1.04 (1.00- 1.10) .018* 
miR-205 1.00 (1.00 – 1.00) .039* 
Age Mean 1.88 (0.98 – 3.58) .050* 
Median miR-192   1.33 (0.72 – 2.45) .364 
Median mirR-200c 1.46 (0.8 – 2.67) .222 
Median miR-205  1.46 (0.79 – 2.69) .226 
3-miRNA panel 1.97 (1.06 – 3.65) .032* 
Stage 1.89 (0.99 – 3.58) .050* 
Multivariate Cox Regression HR (95% CI) P 
Age Mean 2.63 (1.32 – 5.25) .006 
Stage 2.09 (1.07 – 4.08) .030 
3-miRNA panel 2.10 (1.11 – 4.04) .022 
 
Table 4.1.3. Univariate and Multivariate Analysis of overall survival in 50 SCLC patients 
Abbreviations: HR, Hazard ratio; CI, Confidence interval; *, significant variables included in the multivariate 
analysis. Reference categories. Sex : male gender; Age: values less the than the mean; Median  miR-192, Median 
mirR-200c, Median miR-205: values less than the correspondent medians; 3-miRNA panel: group A (score 0-1); 
Stage: group LD  (limited-diseased) 
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4.2 Results of SCC. 
The mean age at diagnosis was 69.9 years (range, 52-83 years); 76 patients (88%) were male, and 
10 were female (12%). At the end of the study, 13 patients (15%) had recurrence, and 31 (36%) had 
died. The causes of mortality included tumour-related death or tumour-related complications. The 
median overall survival (OS) was 1436 days (range, 0-2561 days).  
Forty-four patients (51%) were in stage I, 29 (34%) in stage II, and 13 (15%) in stage III according 
to the WHO classification. Twenty-six patients (30%) had lymph node metastasis; in 33 patients 
(38%) SCC was well or moderately differentiated, and in 53 (62%) was poorly differentiated. All 
patients were former (n=57; 66%) or current (n=29; 34%) smokers. Thirty-one patients (36%) had 
previous cancer diagnosis (five years before the diagnosis of SCC); summarize in Table 4.2.1. 
 
4.2.1 Association Between Clinical Variables, and OS and DSS 
The clinical variables were: stage of disease, grading, lymph node status, previous diagnosis of 
malignant tumours and recurrence. As expected, better OS and DSS were found in patients without 
recurrence (respectively P = .0050 and P = .0003), tumours in stage T 1 and 2 (according to TNM 
classification; respectively P = .0236 and P = .0017), and without lymph node metastases 
(respectively P = .0064 and P = .0026), patients with clinical stage I (respectively P = .0049 and P = 
.0003), and without previous diagnosis of malignant tumours (only for OS P = .0049), as shown in 
table 4.2.2 
 
4.2.2 Relative expression of miRNAs between SCCs and the healthy controls 
RNA was successfully extracted from all FFPE samples. Mir-205 and miR-200c were significantly 
overexpressed (P <.0001 and P. 021) in patients with SCC than in healthy controls, whereas miR-
192 was significantly down-expressed (P .0002) in patients with SCC than in the healthy controls. 
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Variables Values 
Age (range years) 69.9 (52-83) 
  N° of cases (%) 
Sex 
Male 76 (88) 
Female 10 (22) 
Smoking Status 
Former  57 (66) 
Current  29 (34) 
Diabetes   
Yes 11 (13) 
No 75 (87) 
Hypertension 
Yes 34 (40) 
No 52 (60) 
BPCO 
Yes 12 (14) 
No 74 (86) 
Previous Cancer Diagnosis  
Yes 31 (36) 
No 55 (64) 
T parameter of TNM  
1 23 (27) 
2 48 (56) 
3 14 (16) 
4 1 (1) 
Lymph Node Status 
N0 60 (70) 
N+ 26 (30) 
Staging 
I 44 (51) 
 II 29 (34) 
III 13 (15) 
Grading 
G2 33 (38) 
G3 53 (62) 
Recurrence 
Yes 13  (15) 
No 73 (85) 
Table 4.2.1. Main Clinicopathologic Characteristics of 86 SCC Patients 
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Variables OS (months) log rank Test DSS  (months) log rank Test 
Mean Age  
69.9 <  59.03 P = .7881 61.65 P = .4337 
69.9 >  61.31  67.28   
Sex  
Male 60.86 P = .9689 64.98 P = .8224 
Female 60.36  67.05   
Smoking Status  
Former  61.88 P = .8168 66.30 P = .6982  
Current  59.02  63.39   
Diabetes  
Yes 55.08 P = .5476 60.58 P = .5369 
No 62.95  67.44   
Hypertension  
Yes 57.98 P = .3792  64.53 P = .6502 
No 63.68  66.83   
BPCO  
Yes 75.06 P = .1286 79.82 P = .0986 
No 58.35  62.73   
Previous Cancer Diagnosis   
Yes 49.09 P = .0049* 57.91 P = .0720 
No 67.91  70.29   
T parameter of TNM  
T1-2 65.21 P = .0236* 71.01 P = .0017* 
T3-4 45.95  45.95   
Lymph Node Status  
N0 68.04 P = .0064* 72.92 P = .0026* 
N+ 42.20  45.41   
Clinical staging  
I 71.50 P = .0049* 78.39 P = .0003* 
 II-III 51.23  53.61   
Grading  
G2 64.04 P = .3670 67.84 P = .3854 
G3 59.35  63.79   
Recurrence  
Yes 41.60 P = .0050* 41.60 P = .0003* 
No 65.31  70.98   
Table 4.2.2. Survival analysis of 86 SCC patients and Clinicopathologic Characteristics 
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4.2.3 Association between a single miRNA,  and OS and DSS 
Camp et al. have developed a graphical method, the X-tile plot that illustrates the presence of 
substantial tumour subpopulations and shows the robustness of the relationship between a 
biomarker and outcome by construction of a two dimensional projection of every possible 
subpopulation. An “optimal” cut-off value for each miRNA was determined by utilizing the X-Tile 
software application (Camp et al. 2004). This enables the division of patients into high-expression 
(score 1) and low-expression groups (score 0) (Figure 4.2.1). 
 
         
 
Figure 4.2.1. Screenshot of X-Tile software. Cut-off of 2-ΔΔCt miR-192 ≥ 0.515; Cut-off of 2-ΔΔCt miR-200c ≥ 
2.341; Cut-off of 2-ΔΔCt miR-205 ≥ 13.85. 
 
Interestingly, a statistically significant difference in OS between high- and low-expression groups 
was found only for miR-192 (P = .031). Moreover, patients with high expression levels of each 
single miRNA had better DSS than the patients with low levels, although miR-205 is not 
statistically significant (miR-192, P = .0086; miR-200c; P = .019; miR-205 P = .056) (Table 4.2.3). 
 
 
 
 
 
 
 
 
! 40!
miRNAs  OS (months) log rank Test DSS  (months) log rank Test 
miR-192   
n=49 (57%) Down 54.20 P = .0314* 57.89 P = .0086* 
n=37 (43%) Up   68.68  73.40   
miR-200c   
n=56 (65%) Down   57.09 P = .1111 60.38 P = .0191* 
n=30 (35%) Up 66.97  73.03   
miR-205  
n=60 (70%) Down   58.92 P = .2820 61.89 P = .0560 
n =26 (30%) Up  65.92   73.81   
Table 4.2.3. Survival analysis of 86 SCC patients and miRNAs expression 
 
4.2.4 Multivariate analysis  
The variables putatively associated with the OS and DSS were individually analyzed by use of 
univariate Cox proportional hazards regression model. Significant variables in the univariate 
analysis were added to a multivariate model, and forward elimination was applied at the 5% 
significance level.  
Previous diagnosis of malignant tumours, Lymph Node Status, Recurrence and miR-192 (high- 
versus low-expression groups) were the only significant predictors for OS  (Table 4.2.4). 
Furthermore, Clinical staging I vs II-III, and miR-192 (high- versus low-expression groups) were 
the only significant predictors for DSS (Table 4.2.5). 
 
 Univariate Cox regression Multivariate Cox Regression 
Covariate for OS HR (95% CI) P Value HR (95% CI) P Value 
Sex 1.02 (0.31 to 3.34)   .969     
Mean Age 0.90 (0.44 to 1.83)   .788     
Smoking Status 1.09 (0.51 to 2.32)   .817     
Diabetes 1.34 (0.51 to 3.49) .549     
Hypertension 1.37 (0.67 to 2.77) .381     
BPCO 0.34 (0.08 to 1.44)  .146     
Previous Cancer Diagnosis  2.65 (1.31 to 5.37)   .006* 2.85 (1.37 to 5.91) .005 
T parameter of TNM 1-2 vs 3-4 2.39 (1.02 to 5.19)   .028*     
Lymph Node Status 2.62 (1.28 to 5.37)   .008* 3.29 (1.56 to 6.94) .002 
Staging I vs II-III 2.82 (1.33 to 6.00)   .007*     
Grading 1.43 (0.65 to 3.13)   .369     
Recurrence 2.91 (1.33 to 6.35)   .007* 2.24 (1.00 to 4.99) .049 
miR-192 0.44 (0.21 to 0.94)   .036* 0.41 (0.19 to 0.89) .026 
miR-200c 0.52 (0.23 to 1.17)   .117     
miR-205 0.64 (0.28 to 1.43)   .285     
Table 4.2.4. Univariate and Multivariate Analysis of OS in 86 SCC patients 
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 Univariate Cox regression Multivariate Cox Regression 
Covariate for DSS HR (95% CI) P Value HR (95% CI) P Value 
Sex 1.18 (0.27 to 4.98) .822     
Mean Age 0.72 (0.32 to 1.61) .435    
Smoking Status 1.18 (0.50 to 2.76) .698    
Diabetes 1.40 (0.47 to 4.10) .539    
Hypertension 1.20 (0.53 to 2.70) .650    
BPCO 0.21 (0.02 to 1.58)  .133    
Previous Cancer Diagnosis  2.06 (0.92 to 4.60) .078    
T parameter of TNM 1-2 vs 3-4 3.48 (1.52 to 7.96)   .003*    
Lymph Node Status 3.29 (1.45 to 7.45) .004*    
Staging I vs II-III 5.12 (1.91 to 13.70)   .001* 4.63 (1.67 to 12.87) .003 
Grading 1.47 (0.61 to 3.57) .388    
Recurrence 4,20 (1.82 to 9.64) .000*   
miR-192 0.30 (0.12 to 0.77)   .012* 0.31 (0.12 to 0.79) .015 
miR-200c 0.29 (0.10 to 0.86) .027*    
miR-205 0.36 (0.12 to 1.06) .066    
Table 4.2.5. Univariate and Multivariate Analysis of DSS in 86 SCC patients 
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4.2.5 Significant predictors of OS and DSS, and miRNA 
In order to investigate the possible influence of single miRNA expression in independent predictive 
variable subgroups we performed a Kaplan-Meier analysis using log rank. 
For brevity and clarity, we reported only significant results.  
High expression levels of miR-192 were associated with a better OS among the subgroups of 
patients with a) metastatic lymph-node (P = .005), b) without recurrence (P = .045), and c) . In 
addition, high expression levels of miR-200c were associated with better OS among the subgroup of 
patients without previous diagnosis of malignant tumours (P = .030) (Figure 4.2.2). Lastly, in 
patients with clinical stages II and III, high expression levels of miR-192 and miR-205 were 
associated with better DSS than patients with low expression levels (P = .006 and P = .028) (Figure 
4.2.3). 
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Figure 4.2.2. Survival (OS) analysis based on independent predictive variables subgroups and 
miRNAs expression.  
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Figure 4.2.3. Survival specific (DSS) analysis based on independent predictive variables subgroups 
and miRNAs expression.  
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5. DISCUSSION 
 
5.1 SCLC 
The diagnosis of SCLC could be suspected on the basis of clinical presentation and imaging studies 
but pathologic confirm is required. Cytology from bronchoscopy or from fine-needle aspiration 
biopsies (FNAB) are often the preferred approaches in order to achieve the diagnosis, either from 
primary tumour or from metastasis because the minimal trauma to the patient and the ease of 
sample acquisition. The prognosis of SCLC is poor; best prognostic factors include limited stage 
disease (TNM stages I-III), age < 70 years, female sex, performance status <1 and baseline 
laboratory test (LDH, alkaline phosphatise and sodium) (van Meerbeeck et al. 2011). Unlike other 
lung cancers, molecular markers of SCLC able to predict the prognosis or driving the choice to 
therapy are still lacking. 
In the last few years, miRNAs have been considered promising biomarkers in order to discriminate 
different subtypes of cancer, and to foresee prognosis and response to the conventional 
chemotherapy in several types of human cancers. Moreover, the higher stability of miRNAs 
compared with mRNAs, allowed to obtain high-quality miRNA from a wide range of tissue and cell 
sources taken during the routine diagnostic procedures. However, to the best of our knowledge, no 
authors have investigated the feasibility of miRNA analysis expression in different cytology 
samples, fixed in several ways, and the lower cut off of cellularity below which the results are not 
reliable.  
In our study, we were able to isolate sufficient quantity of miRNAs from SCLC cells obtained by 
FNABs of lung or metastatic lymph nodes either from cell blocks or by scraping cells from slides, 
fixed in ethanol, and by BWs fixed in Dubosq-Brazil. miRNA analysis was reliable also in low-
cellular samples with a minimum of 80 cancer cells.  
In our cohort of patients, the average age at diagnosis was 65.8 years: the group of patients older 
than the average age showed a strong tendency with a poor prognosis. Moreover, we compared the 
OS between patients with limited and extensive stage disease. As expected, also in our cohort, the 
patients with limited-stage disease showed better survival than patients with extensive-stage 
disease. Both results are in line with the findings of literature (van Meerbeeck et al. 2011; Amini et 
al. 2014). 
The comparison between miRNA panel expression, stage at diagnosis and age, indicated that high 
expression of miRNA was associated with poor OS in the group of older patients with extensive-
stage disease. Moreover, we found that high expression of the selected miRNA panel (miR-192, 
miR-200c and miR-205) is independently associated with short overall survival in SCLC.  
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Different molecular mechanisms are involved in the effect of these miRNAs: miR-192 target genes 
involved in the repair, biogenesis and damage DNA processes, miR-205 seems to act through 
angiogenesis by inhibiting TIMP-3 and RECK and increasing MMPs levels, miR-200c plays a role 
in the regulation of the PI3K/Akt/mTOR pathway. 
Moreover, miR-192 target genes involved in DNA biogenesis as dihydrofolate reductase (Song et 
al., 2008), TYMS (Khella et al. 2013) and DNA repair ERCC 3-4 (Xie et al. 2011). ERCC3 and 
ERCC4, two proteins involved in NER pathway, were down-regulated by miR-192, with 
consequent impairing of NER machinery (Xie et al. 2011). 
Many studies examined the prognostic value of miR-200c expression in human cancers. Liu et al. 
(2012) showed a miR-200c overexpression as a marker of poor prognosis in NSCLC patients. 
Overexpression of miR-200c influences tumour growth and survival by regulating the expression of 
tumour suppressive PTEN and subsequent activation of the Akt signaling pathway in many 
carcinomas.  
A decrease in functional PTEN causes activation of Akt and FAK and the expression of the MMPs 
(Kwiatkowska et al. 2011). As MMPs appear to be essential for tumour invasion and metastatic 
spread, characterizing their expression may help to determine a treatment or prognosis in patients 
whit cancer, included NSCLC. A study shows miR-205 directly target two key upstream inhibitors 
of MMPs, tissue inhibitor of metalloproteinases 3 (TIMP3) and reversion inducing cysteine-rich 
protein with kazal motifs (RECK) that in turn led to ECM degradation. Overexpression of miR-205 
was detected in tissues from multiple subtypes of NSCLC that led to increased proliferation and 
angiogenesis (Cai et al., 2013). Oncogenic miR-205, overexpressed in NSCLC cell lines and 
tissues, was shown to enhance cell growth, metastasis, and chemoresistance to Cisplatin of A549 
cells by targeting PTEN (Liu et al., 2013). 
In conclusion, we have identified panel of miRNA as potential prognostic markers in SCLC. 
Although further studies in larger cohorts are needed, our findings have revealed the usefulness of 
microRNAs as potential prognostic markers in SCLC. 
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5.2 Squamous cell carcinoma 
In this study, multivariate analysis indicated that in our cohort of patients with SCC, better OS is 
related to stage I disease, absence of lymph node metastasis and recurrence, absence of previous 
diagnosis of malignant tumours and, importantly, high expression levels of miR-192, whereas better 
DSS is related to stage I disease and once high expression levels of miR-192.  
If the better OS and DSS were expected in favourable clinical parameters, the most important 
finding of our study was the identification of one specific miRNA whose high expression seem to 
predict better prognosis. 
As reported above in the part of the study concerning SCLC, miR-192 has been involved in several 
oncogenic pathways. In SCLC, isolated expression levels of miR-192 did not reach statistical 
significance in terms of survival rate. Moreover, in lung adenocarcinoma, miR-192 seem favour 
cellular mechanism of chemoresistence in in vitro experiments, whereas, to the best of our 
knowledge, studies relating expression levels of miR-192 in adenocarcinoma from clinical setting 
are lacking.  
Experimental data have shown that miR-192 is involved in the processes of chemo-resistance, 
progression, metastasis and cell proliferation, and functional experiments have indicated a tumor 
suppressor role of miR-192 in lung (Feng et al. 2011), breast (Hu et al. 2013), epithelial ovarian 
cancers (Nakano et al. 2013) and in pancreatic adenocarcinoma (Botla et al. 2016). However, to the 
best of our knowledge, the prognostic significance of miR-192 in SCC has been investigated in only 
one clinical report, therefore our results are difficulty comparable with literature data. Skrzypski et 
al. (2014) evaluated the expression profiling of a panel of miRNAs, including miR-192, in a cohort 
of patients with operable SCC. In that report the authors found that low expression levels of miR-
192 were related with lower probability of distant metastasis and therefore were related to a worst 
prognosis. The conflicting results compared to ours, could be partially explained with the use of 
different methodologies for miRNA amplification, with the different clinical end point and selection 
of patients.  
In conclusion, the results obtained by our studies strongly support the possibility of the use of 
selected miRNAs as prognostic biomarkers in both cytologic and histologic  clinical samples of 
lung malignant tumours. 
Since the mechanisms by which miRNAs regulate gene expression are not completely understood 
and the function of a specific miRNA can vary in different organs, tissues and histologic types of 
cancer, the translational significance of low or high expression of miRNAs have to be validated in 
the future extending the number of patients studied to reach more statistical significance.! 
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